Navigation Links
Ambry Genetics Shares New Data on Genetic Causes for Neurodevelopmental Conditions, Further Adding to Growing Body of Evidence in Neurology
Date:3/11/2016

ALISO VIEJO, Calif., March 11, 2016 /PRNewswire/ -- Ambry Genetics (Ambry), a leader in clinical genetic diagnostics and genetics software solutions, announced data identifying potential new genetic links to neurodevelopmental conditions. The findings, shared today in oral platform presentations at the American College of Medical Genetics and Genomics (ACMG) 2016 Annual Clinical Genetics Meeting in Tampa, FL, were based on genetic testing results conducted by Ambry, including diagnostic exome sequencing (DES).

"Neurodevelopmental disorders represent a challenging diagnosis because the underlying cause is not always readily understood," said Aaron Elliott, Ph.D., Chief Operating Officer and Interim Chief Scientific Officer, Ambry Genetics. "With exome sequencing and other genetic tests, we are starting to uncover disease-causing gene mutations in neurology that may have important clinical implications.  The findings presented today in these oral presentations further add to our growing body of data that we hope will offer healthcare providers and their patients with some of the answers they are seeking."

KIAA2022 Gene Mutations and Epileptic Encephalopathy in Women (Abstract #43)
The first oral platform presentation's study evaluated whole genome sequencing, whole exome sequencing, and next generation sequencing panel data in females with neurodevelopmental disorders and epilepsy to identify patients with mutations in the KIAA2022 gene, found on the X chromosome.  The gene encodes a protein of unknown function, and is highly expressed in postmitotic neurons (defined as cells that no longer divide) in the fetal and adult brain.  It is thought to play a role in early brain development. Researchers looked for female patients with de novo mutations, meaning that the genetic alteration appeared for the first time in that patient and was not previously present in other family members.

Among 11 female patients identified with previously unreported de novo loss-of-function KIAA2022 mutations, 82% (n=9) had refractory generalized epilepsy with onset in infancy or early childhood.  Myoclonic seizures (brief muscle jerks) were the predominant type of seizure, occurring in 8 out of the 9 females, followed by absence seizures, or lapses in awareness (7 out of 9), and generalized tonic-clonic, or convulsive seizures (6 out of 9).

Cognitive outcomes ranged from mild to severe intellectual disability.  All but one patient had limited speech and language skills, and autism or autistic features were found in more than half of the female patients (6 out of 11). Behavioral problems such as aggression, hyperactivity, and attention-deficit hyperactivity disorder (ADHD) were identified in 8 out of 11 females.

"While the link between KIAA2022 mutations and neurodevelopmental conditions has been previously established in males, little is known about alterations in this gene in females," said Katherine Helbig, MS, LCGC, a genetic counselor at Ambry Genetics and study investigator.  "We observed that, in females, the alterations in this gene cause a distinct trait, characterized by refractory myoclonic epilepsy with mild to severe intellectual disability, autistic features, and behavioral disturbances. This is different from males, who often have more severe intellectual disability and dysmorphic features, and suggests more research is needed to explain these differences."

ASPM Gene Alterations and Marked Microcephaly (Abstract #44)
For the second oral platform presentation's study, Ambry completed postmortem DES on a fetus with marked microcephaly to identify a potential genetic cause. Microcephaly is a congenital birth defect in which the baby's head is smaller than expected, and is associated with incomplete brain development when severe.  The ASPM gene encodes the abnormal spindle-like microcephaly-associated protein, and alterations in this gene are associated with primary microcephaly 5, a condition characterized by decreased occipitofrontal circumference and intellectual disability.

While there was no reported family history of marked microcephaly or other findings, DES results revealed compound heterozygous ASPM alterations in the fetal sample, meaning that the sample had two pathogenic recessive mutations causing the genetic disease.

Overall, the data support that ASPM mutations were the cause of the genetic condition in the fetus.  In addition, the findings suggested that the parents have a 25% chance of having an affected pregnancy in the future, which could not have been accurately concluded based on prenatal ultrasound findings alone.

"The findings from this case illustrate the utility of diagnostic exome sequencing in helping parents of children with existing neurodevelopmental syndromes to understand the chance of recurrence in future pregnancies," said Christina L. Alamillo, MS, CGC, genetic counselor, Clinical Genomics at Ambry Genetics and lead study author. "This case also adds to the current literature by describing the phenotypic features observed in a fetus as a result of compound heterozygous ASPM mutations."

ABOUT AMBRY GENETICS®
Ambry Genetics is a privately-held healthcare company with the most comprehensive suite of genetic testing solutions for inherited and non-inherited diseases.  Since 1999, Ambry has tested approximately half a million patient samples benefiting 90% of all U.S. patients covered by public and private insurers.
Ambry is dedicated to scientific collaboration by offering its rapidly growing database of anonymized patient records free to the global medical research community to fulfill the promise of the human genome to cure or manage all human disease.  Ambry is dedicated to the belief that human health should not be patented or owned, and genomic data should be freely shared so we can try to cure all disease.  For more information about Ambry Genetics, visit www.ambrygen.com.

To access Ambry Genetics' public database of human genome data and learn more about the company's commitment to collaboration and sharing, visit www.AmbryShare.com.

 

Contacts:
Ambry Genetics
Humberto Huerta
Director of Marketing
hhuerta@ambrygen.com
949-633-5285

Ogilvy Public Relations
Jess Sims
jess.sims@ogilvy.com
347-803-3645

References:1.

Helbig KL, et al. De novo Mutations of KIAA2022 in Females Cause Epileptic Encephalopathy; (Abstract #43). Presented at the 2016 ACMG Annual Clinical Genetics Meeting, March 9-11, 2016, Tampa, FL.2.

Alamillo CL, et al. Clinical Diagnostic Exome Sequencing Identified Compound Heterozygous ASPM Gene Alterations in a Fetus with Marked Microcephaly. (Abstract #44). Presented at the 2016 ACMG Annual Clinical Genetics Meeting, March 9-11, 2016, Tampa, FL.

 

Logo - http://photos.prnewswire.com/prnh/20160114/322413LOGO 


'/>"/>
SOURCE Ambry Genetics
Copyright©2016 PR Newswire.
All rights reserved


Related biology technology :

1. Ambry Genetics Launches New Neurodevelopmental Genetic Testing Panel
2. Ambry Genetics to Present Seven Abstracts at Upcoming ACMG Annual Clinical Genetics Meeting
3. NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
4. GeneTex Introduces New Mouse Monoclonal Antibody Against the Ten-Eleven Translocation 1 (TET1) Protein for DNA Methylation/Epigenetics Research
5. Todays Technical View: Elan Corp., Amarin, Seattle Genetics, and Cubist Pharma
6. Signal Genetics LLC Announces Update to MyPRS™ Gene Expression Profiling Assay for Multiple Myeloma
7. Signal Genetics Announces Publication of BreastPRS™ Validation Study with Weill Cornell Medical College, New York
8. Cytogenetics - Technologies, Markets and Companies - 2013
9. Population Genetics Assigns Asymmetric Adaptor Library Construction Patent To New England Biolabs
10. Molecular Cytogenetics Market is Expected to Reach USD 1.97 Billion Globally in 2019: Transparency Market Research
11. AvidBiotics Announces Research Collaboration with Full Spectrum Genetics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/3/2019)... ... October 01, 2019 , ... Today Cereset®, the only proven ... point of its randomized research trial for individuals with persisting symptoms following mild-Traumatic ... of a non-invasive technology which compares tones delivered to a subject’s brain guided ...
(Date:10/3/2019)... Va. (PRWEB) , ... October 02, 2019 , ... eKare’s ... prestigious NHS Digital Health Accelerator run by the East Midlands Academic Health Science Network ... the adoption of technology in NHS by providing support to develop and deploy solutions ...
(Date:9/24/2019)... WEST LAFAYETTE, Ind. (PRWEB) , ... ... ... Pharma LLC will be presenting their latest research in the area of ... Monday, November 4th, Dr. Pamela Smith, COO of Improved Pharma, will present ...
(Date:9/24/2019)... ... September 24, 2019 , ... The Grain Foods Foundation is ... Advisory Board. Dr. Holscher is an Assistant Professor of Nutrition in the Department ... the University of Illinois Urbana-Champaign, where she has affiliate appointments with the Institute ...
Breaking Biology Technology:
(Date:9/25/2019)... ... September 25, 2019 , ... The esteemed dental ... 20,000 dental implants for a variety of procedures, including single tooth replacement, new ... implants. Dental implants offer patients permanent tooth replacement solutions that look ...
(Date:9/24/2019)... ... September 23, 2019 , ... ... Cambridge, MA, announce today that Holotype HLA and other Omixon products will be ... the American Society for Histocompatibility and Immunogenetics (ASHI) in Pittsburgh, PA. ...
(Date:9/22/2019)... ... 2019 , ... A new report from Strategic Directions International ... products. The report, Lab Instrumentation Markets for Pharmaceuticals, Biopharmaceuticals, & CROs , ... the largest source of demand for laboratory instrumentation. , With the rise ...
Breaking Biology News(10 mins):